drugset / Trial / NCT04676139

The Safety and Efficacy of Fluoxetine for Refractory Primary Mono-symptomatic Nocturnal Enuresis in Children

NCT04676139

Phase 3 Unknown 100 enrolled Mansoura University
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine whether there is a role for the selective serotonin reuptake inhibitors, fluoxetine, as therapy in the treatment of refractory primary monosymptomatic nocturnal enuresis in children , and whether there are side effects involved.

Timeline

Start
2020-07-01
Primary completion
2022-10
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluoxetine Small molecule 10 mg

Indications